ARSL and advanced heart failure: SERCA2a is a sarcoplasmic reticulum calcium adenosine triphosphate (ATP)-ase that is deficient in patients with advanced heart failure.25,26 Both trials met their primary safety endpoints and demonstrated that gene therapy can be safely administered in patients with advanced heart failure.